Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL

NCT06393985 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

B-cell Acute Lymphoblastic Leukemia

Interventions

DRUG: Decitabine, venetoclax and blinatumomab

Sponsor

The First Affiliated Hospital of Soochow University